Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.17 – $0.40
12% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $63.56B | $65.25B | $59.87B | $61.79B | $66.81B | $70.17B | $69.81B | $67.83B |
| Cost of revenue | $44.64B | $47.30B | $44.15B | $45.53B | $48.78B | $50.90B | $50.54B | $52.14B |
| Gross profit | $18.91B | $17.95B | $15.72B | $16.26B | $18.03B | $19.26B | $19.26B | $15.70B |
| Gross margin | 29.8% | 27.5% | 26.3% | 26.3% | 27.0% | 27.5% | 27.6% | 23.1% |
| R&D | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | $7.32B | $8.01B | $6.63B | $7.04B | $8.09B | $8.51B | $8.69B | $5.42B |
| EBITDA | $10.23B | $10.82B | $9.81B | $10.25B | $11.24B | $11.37B | $12.30B | $9.00B |
| Net income | $5.61B | $6.18B | $5.15B | $5.44B | $6.22B | $6.44B | $6.50B | $6.01B |
| Net margin | 8.8% | 9.5% | 8.6% | 8.8% | 9.3% | 9.2% | 9.3% | 8.9% |
| EPS (diluted) | 0.43 | 0.47 | 0.39 | 0.41 | 0.47 | 0.49 | 0.49 | 0.46 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $68.5B | $0.46 | $0.44–$0.49 | 1 |
| 2027 | $71.0B | $0.49 | $0.46–$0.51 | 1 |
| 2028 | $73.7B | $0.51 | $0.49–$0.54 | 1 |
| 2029 | $72.9B | $0.51 | $0.49–$0.54 | 1 |
Forward consensus · source: Financial Modeling Prep
HOME PRODS CNTR PCL FGN
No one on the platform currently holds HPCRF.
No tracked institution reports a position in HPCRF as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-04-23 | $0.2200 | 2026-05-07 |
| 2025-09-11 | $0.1600 | 2025-09-24 |
| 2025-04-23 | $0.2500 | 2025-05-08 |
| 2024-09-11 | $0.1800 | 2024-09-24 |
| 2024-04-22 | $0.2200 | 2024-05-08 |
| 2023-09-12 | $0.1800 | 2023-09-27 |
| Execution date | Ratio |
|---|---|
| 2011-10-07 | 8-for-7 |
| 2011-04-12 | 7-for-6 |
| 2009-10-12 | 19-for-10 |
No one on the platform has traded HPCRF yet.
| +0.00% |
| $3.9B |
| — |
| MRCIFMercari, Inc. | $15.88 | +0.00% | $2.6B | — |
| NPSKYNSK Ltd. | $14.36 | +0.00% | $3.5B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 0.4× earnings vs its 0.7× historical median P/E.
Fair value ≈ $0.36 · price $0.20 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.